Lorraine Mooney

TL;DR: The findings show that AZD4547 is a novel selective small-molecule inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclinical models and is under clinical investigation for the treatment ofFGFR-dependent tumors.

TL;DR: Combining lactate transport inhibition by AZD3965 with GLS1 inhibition in vitro, enhanced cell growth inhibition and cell death compared to monotherapy treatment and the ability to combine AZD 3965 with novel, and standard-of-care inhibitors offers novel combination opportunities in haematological cancers.

TL;DR: Novel mechanisms by which PI3Kα/δ inhibitors interact with the immune system are revealed and the clinical compound AZD8835 is validated as a novel immunoncology drug, independent of effects on tumor cells, support further clinical investigation ofPI3K pathway inhibitors as immuno- oncology agents.

TL;DR: This longitudinal profiling of syngeneic models enables pharmacodynamic time point selection within each model, dependent on the immune population of interest, and will provide a framework for characterization and enable the selection of the optimal models for immunotherapy combinations.

TL;DR: Novel dynamic transcript biomarkers of FGFR inhibition that were validated in a number of in vivo models, and which are more robustly modulated byFGFR inhibition than some conventional downstream signaling protein biomarkers are identified.